NO20054472L - 2-(butyl-1-sulfonylamino)-N-[1(R)-(6-metoksy-pyridin-3-yl)-propyl]-benzamid, dets anvendelse som medikament samt farmasoytiske preparater inneholdende forbindelsen - Google Patents

2-(butyl-1-sulfonylamino)-N-[1(R)-(6-metoksy-pyridin-3-yl)-propyl]-benzamid, dets anvendelse som medikament samt farmasoytiske preparater inneholdende forbindelsen

Info

Publication number
NO20054472L
NO20054472L NO20054472A NO20054472A NO20054472L NO 20054472 L NO20054472 L NO 20054472L NO 20054472 A NO20054472 A NO 20054472A NO 20054472 A NO20054472 A NO 20054472A NO 20054472 L NO20054472 L NO 20054472L
Authority
NO
Norway
Prior art keywords
sulfonylamino
benzamide
pyridin
methoxy
propyl
Prior art date
Application number
NO20054472A
Other languages
English (en)
Norwegian (no)
Inventor
Klaus Wirth
Joachim Brendel
Heinz Goegelein
Gert Ulrich Kuerzel
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of NO20054472L publication Critical patent/NO20054472L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/63One oxygen atom
    • C07D213/64One oxygen atom attached in position 2 or 6
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
NO20054472A 2003-03-18 2005-09-27 2-(butyl-1-sulfonylamino)-N-[1(R)-(6-metoksy-pyridin-3-yl)-propyl]-benzamid, dets anvendelse som medikament samt farmasoytiske preparater inneholdende forbindelsen NO20054472L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10312073A DE10312073A1 (de) 2003-03-18 2003-03-18 2-(Butyl-1-sulfonylamino)-N-[1(R)-(6-methoxy-pyridin-3yl)-propyl]-benzamid, dessen Verwendung als Medikament sowie dieses enthaltende pharmazeutische Zubereitungen
PCT/EP2004/002247 WO2004083157A1 (de) 2003-03-18 2004-03-05 2-(butyl-1-sulfonylamino)-n-[1(r)-(6-methoxy-pyridin-3-yl)-propyl]-benzamid, dessen verwendung als medikament sowie dieses enthaltende pharmazeutische zubereitungen

Publications (1)

Publication Number Publication Date
NO20054472L true NO20054472L (no) 2005-09-27

Family

ID=32920928

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054472A NO20054472L (no) 2003-03-18 2005-09-27 2-(butyl-1-sulfonylamino)-N-[1(R)-(6-metoksy-pyridin-3-yl)-propyl]-benzamid, dets anvendelse som medikament samt farmasoytiske preparater inneholdende forbindelsen

Country Status (21)

Country Link
EP (1) EP1606237A1 (https=)
JP (1) JP2006520343A (https=)
KR (1) KR20050110681A (https=)
CN (1) CN100361943C (https=)
AR (1) AR043622A1 (https=)
AU (1) AU2004222137A1 (https=)
BR (1) BRPI0408441A (https=)
CA (1) CA2519022A1 (https=)
DE (1) DE10312073A1 (https=)
HR (1) HRP20050815A2 (https=)
MA (1) MA27749A1 (https=)
MX (1) MXPA05009763A (https=)
MY (1) MY176510A (https=)
NO (1) NO20054472L (https=)
NZ (1) NZ542476A (https=)
PE (1) PE20050307A1 (https=)
RS (1) RS20050690A (https=)
RU (1) RU2333202C2 (https=)
TW (1) TW200500342A (https=)
WO (1) WO2004083157A1 (https=)
ZA (1) ZA200506328B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004009931A1 (de) * 2004-02-26 2005-09-15 Aventis Pharma Deutschland Gmbh Kv1.5-Blocker zur selektiven Steigerung der Vorhofkontraktilität und Behandlung der Herzinsuffizienz
US7569589B2 (en) 2004-07-29 2009-08-04 Merck & Co., Inc. Potassium channel inhibitors
DE102005028845A1 (de) * 2005-06-22 2006-12-28 Sanofi-Aventis Deutschland Gmbh Substituierte Heterocyclen, ihre Verwendung als Medikament sowie enthaltende pharmazeutische Zubereitungen
WO2007015775A2 (en) * 2005-07-22 2007-02-08 Merck & Co., Inc. Potassium channel inhibitors
EP2435407B1 (en) * 2009-05-29 2019-12-25 RaQualia Pharma Inc. Aryl substituted carboxamide derivatives as calcium or sodium channel blockers

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0472053B1 (en) * 1990-08-20 1998-06-17 Eisai Co., Ltd. Sulfonamide derivatives
DE10121003A1 (de) * 2001-04-28 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide, Verfahren zur Herstellung, ihrer Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen

Also Published As

Publication number Publication date
PE20050307A1 (es) 2005-06-08
DE10312073A1 (de) 2004-09-30
TW200500342A (en) 2005-01-01
HK1086819A1 (en) 2006-09-29
RU2005132163A (ru) 2006-04-10
RS20050690A (sr) 2008-04-04
MY176510A (en) 2020-08-12
WO2004083157A1 (de) 2004-09-30
RU2333202C2 (ru) 2008-09-10
ZA200506328B (en) 2006-04-26
MA27749A1 (fr) 2006-02-01
MXPA05009763A (es) 2006-01-27
CN100361943C (zh) 2008-01-16
BRPI0408441A (pt) 2006-04-04
JP2006520343A (ja) 2006-09-07
NZ542476A (en) 2008-05-30
CN1756728A (zh) 2006-04-05
AU2004222137A1 (en) 2004-09-30
KR20050110681A (ko) 2005-11-23
AR043622A1 (es) 2005-08-03
CA2519022A1 (en) 2004-09-30
HRP20050815A2 (en) 2006-09-30
EP1606237A1 (de) 2005-12-21

Similar Documents

Publication Publication Date Title
NO20051600L (no) 1,4-disubstituerte piperidinderivater og anvendelse derav som 11-betaHSD1 inhibitorer
NO20051036L (no) 3,4-disubstituerte syklobuten-1,2-dioner som CXC-kjemokinreseptorligander
NO950297D0 (no) Prolinamidderivater
NO944911L (no) Ikke-peptid-takykininreseptorantagonister
DK1263722T3 (da) Farmaceutiske sammensætninger, som indeholder azetidinderivat, nye azetidinderivater og fremstilling deraf
EP0866059A4 (en) NOVEL HETEROCYCLIC DERIVATIVES AND THEIR MEDICINAL USE
WO2001064642A3 (en) Benzamides and related inhibitors of factor xa
NO20044501L (no) [1,4] diazenino [6,7,1-IJ] kinolin-derivater som antipsykotis og antifedme-midler
CA2296604A1 (en) Crystal modification of a n-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
CA2320233A1 (en) Farnesyl transferase inhibitors having a piperidine structure and process for preparation thereof
WO1999020606A3 (en) Piperidines and piperazines as platelet aggregation inhibitors
NO20055565L (no) Anvendelse av derivater av 2,4-dihydro-[1,2,4]triazol-3-thion som inhibitorer av enzymet myeloperoksidase (MPO)
NO20040881L (no) Orale antidiabetes midler.
GEP20053505B (en) Diphenyl Ether Compounds Useful in Therapy
NO20060146L (no) Benzimidazolderivater, sammensetninger som inneholder slike, fremstilling derav og anvendelse derav
NO20054472L (no) 2-(butyl-1-sulfonylamino)-N-[1(R)-(6-metoksy-pyridin-3-yl)-propyl]-benzamid, dets anvendelse som medikament samt farmasoytiske preparater inneholdende forbindelsen
EP1374868A4 (en) MEDICAMENT FOR THE TREATMENT AND / OR PREVENTION OF DIABETIC ISCHEMIC DISEASES
NO20044091L (no) Anvendelse av substituerte 3-fenyl-5-alkoksy-1,3,4-oksdiazol-2-on for fremstilling av medikamenter som inhiberer pankreatisk lipase
IL149306A0 (en) Benzamidine derivatives and pharmaceutical compositions containing the same
NO20013601L (no) Nye morfolinobenzamidsalter
SE9902268D0 (sv) Pharmaceutically active compounds
PL374919A1 (en) Novel indoline compound and medicinal use thereof
DK0743063T3 (da) Anvendelse af alpha-aminomethyl-3,4-dichlorobenzyl-thioacetamid derivater til fremstilling af et medikament, som hæmmer genvinding af dopamin og forbindelser til dette brug
WO2003064378A3 (de) Verbindungen, die faktor xa-aktivität
ES2098070T3 (es) Derivados de piperidina con una actividad antihistaminica y antileucotrienica.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application